Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Central nervous system (CNS) disorders comprises of a group of neurological disorders that hamper the function of brain and spinal cord. Brain acts as the memory and control unit of the human body while spinal cord is responsible for conduction of sensory signals received from the peripheral nervous system to the motor junctions of the body such as skeletal muscles, smooth muscles, cardiac muscles, and glands. Few of the commonly occurring CNS disorders include stroke, subdural hemorrhage, epidural abscess, meningitis, epilepsy, multiple sclerosis, Huntington chorea, Alzheimer disease, transient ischemic attack, brain or spinal cord tumors, and others. For instance, according to the Alzheimer’s disease fact and figures report 2021, it is estimated that about 6.2 million people in the U.S. falling in the age group 65 and older are currently living with Alzheimer associated dementia in 2021. This report states that the prevalence of CNS disorders such as Alzheimer’s dementia increases with age and it also estimates that the geriatric population is expected to increase to 88 million by 2050.

Global Central Nervous System Disorders Therapeutics Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.

According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 186,240,393 cases and 4,027,861 deaths due to Coronavirus (COVID-19) were reported till July 11, 2021, across the globe.

Impact of COVID-19 on Demand and Supply of Central Nervous System Disorders Therapeutics

The COVID-19 pandemic and the lockdown in various countries across the globe has impacted the financial status of businesses across all sectors. Pharmaceutical industry is one such sector which has been majorly impacted by the pandemic.

The COVID-19 pandemic has impacted the entire supply chain of the pharmaceutical industry mainly due to strict lockdown in several regions. However, the demand for central nervous system therapeutics is expected to increase during the pandemic due to association of neurological conditions with COVID-19 infection.

For instance, according to an article published by Alzheimer's Research & Therapy journal in June 2021, a study by Cleveland Clinic, revealed a close relationship between Coronavirus genes and Alzheimer’s disease. The study showed that SARS-CoV-2 infection led to several pathways related to neuroinflammation and brain microvascular injury, which may lead to cognitive impairment as well. Thus, impact of the Coronavirus (COVID-19) pandemic is expected to fuel the growth of the global central nervous system disorders therapeutics market during the forecast period, owing to rising neurological disorders as a result of COVID-19 infection during the pandemic.

The global central nervous system disorders therapeutics market is estimated to be valued at US$ 131.3 Mn in 2021, and is expected to exhibit a CAGR of 6.4% over the forecast period (2021-2028).

request-sample

Central Nervous System Disorders Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 131.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.4% 2028 Value Projection: US$ 202.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: Neurovascular Diseases, Trauma, Mental Health (Anxiety Disorders, Epilepsy, Others), Degenerative Diseases (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others), Infectious Diseases, Central Nervous System Cancer, Others
  • By Drug Type: Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others
Companies covered:

Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH

Growth Drivers:
  • Increasing prevalence of central nervous system disorders
  • Increasing research and development activities by market players
  • Increasing product launches and approvals
Restraints & Challenges:
  • Time consuming drug development and approval
  • Adverse effects associated with CNS disorder treatment

Figure 1: Global Central Nervous System Disorders Therapeutics Market Share (%) Analysis, By Drug Type, 2021

Central Nervous System Disorders Therapeutics  | Coherent Market Insights

The increasing prevalence of CNS disorders is the major factor that is expected to drive the market growth over the forecast period.

The rising number of CNS disorders cases such as Alzheimer’s disease, Parkinson disease, epilepsy, meningitis, and others is expected to drive growth of global central nervous system disorders therapeutics market over the forecast period. For instance, according to MedScape, in 2019, the global prevalence of Parkinson’s disease was estimated to be 18-328 cases per 100,000 population per year. Moreover, according to the World health organization (WHO) report 2020, about 50 million people around the world were suffering from dementia in 2019. The same source reveals that approximately 10 million new cases of dementia are reported every year, out of which most of the cases are associated with Alzheimer’s disease.

Moreover, increasing number of research and development activities for improving the effectiveness of central nervous system disorders therapeutics is expected to aid in the growth of the market over the forecast period. For instance, in February 2021, Cerevel Therapeutics, LLC, a U.S. based pharmaceutical company initiated phase III clinical trials for its drug Tavapadon which is used to treat Parkinson’s disease. This study is expected to be completed by December 2024.

The rising number of product launches and approvals is expected to drive the growth of the global central nervous system disorders therapeutics market over the forecast period. For instance, in March 2019, Novartis AG, a Swiss pharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for its drug Mayzent used for treatment of multiple sclerosis.

Global Central Nervous System Disorders Therapeutics Market – Restraints

However, growth of the global central nervous system disorders therapeutics market may be hampered, owing to adverse effects associated with CNS disorder drugs and time consuming drug development and approval process. For instance, according to data provided by the Tufts Center for the Study of Drug Development in 2018, new drug development for central nervous system disorders is estimated to be 20% more time consuming than other drugs. Moreover, the same source states that it takes approximately 38% longer time for approval of CNS disorder drugs than other non-CNS drugs.

Global Central Nervous System Disorders Therapeutics Market – Regional Analysis

On the basis of region, the global central nervous system disorders therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global central nervous system disorders therapeutics market over the forecast period, owing to growing investment in CNS disorder therapeutics by the U.S. government. For instance, according to Canada.ca, the official website of the Government of Canada, in 2019, the Canadian Institutes of Health Research invested approximately US$ 200 million for research activities related to dementia and has planned to invest around US$ 31.6 million between 2019 to 2024 in order to boost research and development in the field of neurological disorders such as CNS disorders.

Key players are focused on business strategies such as partnerships and collaborations which are expected to drive growth of the market in North America. For instance, in January 2021, Atalanta Therapeutics, a U.S. based biotechnology company entered into a collaboration with Biogen, a U.S. based biotechnology company and Genentech, a U.S. based biotechnology corporation to co-develop RNAi therapeutics for treatment of neurodegenerative CNS disorders such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. 

Figure 2: Global Central Nervous System Disorders Therapeutics Market Value (US$ Mn), by Region, 2021

Central Nervous System Disorders Therapeutics  | Coherent Market Insights

Global Central Nervous System Disorders Therapeutics Market – Competitive Landscape

Major players operating in the global central nervous system disorders therapeutics market include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH

The nervous system comprises of peripheral nervous system (PNS) and central nervous system (CNS). The CNS consists of spinal cord and brain and the PNS consists of all the neural elements other than the brain and spinal cord i.e. cranial nerves, peripheral nerves, spinal nerves, and neuromuscular junctions. CNS disorders may be caused due to trauma, infections, tumors, blood flow disruption, autoimmune disorders, and others. Trauma such as traumatic brain injury or intracranial injury is a result of external trauma such as vehicle collision, violence, and others. The severity of traumatic brain injury can range from mild to severe depending upon the impact of the traumatic force injuring the head. CNS infection may be caused due to bacteria, protozoa, virus, fungus, and prions. Meningitis, encephalitis, amoebic brain abscess, poliomyelitis, kuru, rabies, malaria, and toxoplasmosis are some of the common CNS infections. Autoimmune disorders such as Parkinson disease and multiple sclerosis affect the nervous system by damaging the neural cells.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for CNS disorders, which could contribute to the growth of the global central nervous system disorders therapeutics market over the forecast period. For instance, in 2017, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company and Ovid Therapeutics Inc., a U.S. based biopharmaceutical company initiated a collaborative clinical trial study to investigate the potential safety and tolerability of novel TAK-935 drug which was co-developed by both the companies. TAK-935 is used to treat epileptic encephalopathy, a group of disorders which cause malfunctioning of cerebral part of the brain. The results of this study show that TAK-935 drug was well tolerated within the test population and also a decreased frequency of seizures was observed during the study period.

Market players are focusing on launch of products, which is expected to strengthen their position in the global central nervous system disorders therapeutics market. For instance, in February 2018, Sandoz International GmbH, a subsidiary of Novartis AG, a Swiss pharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for its product Glatopa (40 mg/mL). Glatopa is the generic form of Copaxone which is developed by Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical company for the treatment of multiple sclerosis. Sandoz International GmbH has taken an initiative known as Sandoz GlatopaCare to offer free of cost support program to help patients suffering from multiple sclerosis in administering Glatopa injection.

Key features of the study:

  • This report provides an in-depth analysis of global central nervous system disorders therapeutics market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global central nervous system disorders therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market

Detailed Segmentation:

  • Global Central Nervous System Disorders Therapeutics Market, By Disease Type:
    • Neurovascular Diseases
    • Central Nervous System Trauma
    • Mental Health
    • Anxiety Disorders
    • Epilepsy
    • Others
    • Degenerative Diseases
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Others
    • Infectious Diseases
    • Central Nervous System Cancer
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Drug Type:
    • Analgesics
    • Anesthetics
    • Anti-Parkinson Drugs
    • Anti-Epileptics
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Region:
    • North America
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Type:
        • Neurovascular Diseases
        • Trauma
        • Mental Health
        • Anxiety Disorders
        • Epilepsy
        • Others
        • Degenerative Diseases
        • Alzheimer's Disease
        • Parkinson's Disease
        • Multiple Sclerosis
        • Others
        • Infectious Diseases
        • Central Nervous System Cancer
        • Others
      • By Drug Type:
        • Analgesics
        • Anesthetics
        • Anti-Parkinson Drugs
        • Anti-Epileptics
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Biogen
    • Otsuka Pharmaceutical Co. Ltd.
    • Merck & Co.
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Johnson & Johnson Private Limited
    • Eli Lilly and Company
    • Sanofi
    • GlaxoSmithKline plc.
    • Boehringer Ingelheim International GmbH

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Type
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • PEST Analysis
    • Industry Trends
    • Pipeline Analysis
    • Key Highlights
    • Epidemiology
    • Pricing Analysis
    • Regulatory Scenario
    • Global Supply Chain Analysis
  4. Global Central Nervous System Disorders Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Demand and Supply of Central Nervous System Disorders Therapeutics
    • Impact of Covid-19 on the Central Nervous System Disorders Therapeutics Market
  5. Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2017-2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Neurovascular Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Trauma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Mental Health
      • Anxiety Disorders
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Epilepsy
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Degenerative Diseases
      • Alzheimer's Disease
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Parkinson's Disease
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Multiple Sclerosis
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Infectious Diseases
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Central Nervous System Cancer
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Central Nervous System Disorders Therapeutics Market, By Drug Type, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Anesthetics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Anti-Parkinson Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Anti-Epileptics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global Central Nervous System Disorders Therapeutics Market, By Region, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
      • Regional Trends
    • North America
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Biogen
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Otsuka Pharmaceutical Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • AstraZeneca
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Johnson & Johnson Private Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 25 figures on "Central Nervous System Disorders Therapeutics Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The global central nervous system disorders therapeutics market is expected to exhibit a CAGR of 6.4% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 131.3 Mn in 2021.
Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH are some of the prominent players operating in the market.
The market is expected to be valued at US$ 202.7 Mn in 2028.
North America is the prominent region in the market.
Increasing number product launches, rising cases of CNS disorders, increasing research and development activities by the market players, and increasing strategic collaborations among the market players are some of the driving factors, which are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.